

| Drug common name | LIFIRAFENIB |
| INN | lifirafenib |
| Description | Lifirafenib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target serine/threonine-protein kinase A-Raf, epidermal growth factor receptor, and serine/threonine-protein kinase B-raf. |
| Classification | Small molecule |
| Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1 |
| PDB | — |
| CAS-ID | 1446090-77-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4209157 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 8762XZS5ZF (ChemIDplus, GSRS) |
